SYNDEVRX, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.syndevrx.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Phase 1
Recruiting
- Conditions
- HR+/HER2-negative Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- SynDevRx, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT05455619
- Locations
- 🇺🇸
SHARP Healthcare, San Diego, California, United States
🇺🇸Hope and Healing Cancer Services, Hinsdale, Illinois, United States
🇺🇸Trinity Health, Ypsilanti, Michigan, United States
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid TumorsNeoplasmAdvanced MalignancyMetastasis
- Interventions
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- SynDevRx, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02743637
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
News
No news found